Saptagir Inks Remdesivir Manufacturing Deal with Jubilant Generics

Saptagir Laboratories, based in Hyderabad and a part of the 900-crore Saptagir Group, declared an exclusive agreement to manufacture intermediates and an Active Pharmaceutical Ingredient (API) for the intravenous drug Remdesivir with Jubilant Generics, a Jubilant Life Sciences firm

The drug will be manufactured at its Hyderabad World Health Organization (WHO) GMP affirmed clean medication product manufacturing plant, obtained at a speculation of ₹75 crore.

Remdesivir is an experimental antiviral medication that Gilead Sciences, Inc. developed as a treatment regimen for covid-19. Gilead went into a non-exclusive licensing agreement with Joyous Life Sciences for distribution to 127 nations. Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has forayed into an exclusive contract with Saptagir Labs to produce Remdesivir.

“This partnership is timely and in line with our strategic growth plans for the company. Our foray into bulk drug manufacturing will open new revenue streams, backed by our extensive global customer base spanning over 50 countries with an array of products targeted at the fast-growing health and wellness segment,” Shilpa Reddy, Promoter and Managing Director, Saptagir Laboratories.

Saptagir gains a strong foothold in an adjacent pharmaceutical industry by making new investments in the WHO-GMP-certified pharmaceutical plant. The strategy is to achieve US FDA certification for the plant and foster solid agreements with an objective to accomplish 500 KL limit in the future.